| Literature DB >> 23449746 |
Lydia B Zablotska1, Rachel S D Lane, Stanley E Frost.
Abstract
OBJECTIVES: Uranium processing workers are exposed to uranium and radium compounds from the ore dust and to γ-ray radiation, but less to radon decay products (RDP), typical of the uranium miners. We examined the risks of these exposures in a cohort of workers from Port Hope radium and uranium refinery and processing plant.Entities:
Year: 2013 PMID: 23449746 PMCID: PMC3586082 DOI: 10.1136/bmjopen-2012-002159
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Basic characteristics of the Port Hope cohort
| Characteristic | All workers with no mining experience | Radium workers | Uranium workers |
|---|---|---|---|
| Total number of individuals | 3000 | 528 | 2472 |
| Males (%) | 2645 (88.2) | 497 (94.1) | 2148 (86.9) |
| Females (%) | 355 (11.8) | 31 (5.9) | 324 (13.1) |
| Lifetime* RDP exposure, WLM, mean (range, SD) | |||
| Males | 13.3 (0–627.6, 45.9) | 43.9 (0–627.6, 86.9) | 6.3 (0–408.2, 24.1) |
| Females | 4.9 (0–62.7, 9.6) | 19.7 (0.5–62.7, 15.5) | 3.5 (0–45.1, 7.5) |
| Lifetime* γ-dose, mSv, mean (range, SD) | |||
| Males | 116.4 (0–5098.8, 312.1) | 325.6 (0.4–5098.8, 562.1) | 67.9 (0–2433.2, 185.7) |
| Females | 36.2 (0–464.7, 69.7) | 129.0 (1.9–329.4, 85.8) | 27.3 (0–464.7, 61.1) |
*Individual exposures cumulated up to the end of follow-up.
mSv, millisieverts; RDP, radon decay products; WLM, working level months.
SMR for various causes of death and 95% CIs, male Port Hope workers (1950–1999)
| Cause of death (ICD-9 code) | Observed | Expected* | SMR (95% CI) | p Value |
|---|---|---|---|---|
| All infectious diseases (1–139) | 8 | 11.88 | 0.67 (0.29 to 1.33) | 0.33 |
| All cancers (140–208) | 266 | 282.46 | 0.94 (0.83 to 1.06) | 0.34 |
| Oesophageal cancer (150) | 6 | 7.19 | 0.83 (0.31 to 1.82) | 0.84 |
| Stomach cancer (151) | 14 | 18.25 | 0.77 (0.42 to 1.29) | 0.38 |
| Colon cancer (153) | 22 | 26.74 | 0.82 (0.52 to 1.25) | 0.42 |
| Rectal cancer (154) | 15 | 9.39 | 1.60 (0.89 to 2.63) | 0.11 |
| Pancreatic cancer (157) | 10 | 14.63 | 0.68 (0.33 to 1.26) | 0.28 |
| Laryngeal cancer (161) | 5 | 4.15 | 1.21 (0.39 to 2.81) | 0.80 |
| Lung cancer (162) | 99 | 91.62 | 1.08 (0.88 to 1.32) | 0.47 |
| Prostate cancer (185) | 21 | 25.81 | 0.81 (0.50 to 1.24) | 0.40 |
| Kidney cancer (189.0) | 6 | 6.91 | 0.87 (0.32 to 1.89) | 0.93 |
| Bladder and other urinary cancer (188, 189.1–189.9) | 11 | 8.27 | 1.33 (0.66 to 2.38) | 0.42 |
| Bladder cancer (188) | 10 | 7.82 | 1.28 (0.61 to 2.35) | 0.52 |
| Brain and other CNS cancers (191–192) | 5 | 7.61 | 0.66 (0.21 to 1.53) | 0.46 |
| Brain cancer (191) | 5 | 6.75 | 0.74 (0.24 to 1.73) | 0.67 |
| NHL (200, 202) | 7 | 8.65 | 0.81 (0.33 to 1.67) | 0.73 |
| All leukaemia (204–208) | 6 | 9.50 | 0.63 (0.23 to 1.37) | 0.33 |
| Diabetes mellitus (250) | 14 | 19.39 | 0.72 (0.39 to 1.21) | 0.26 |
| All nervous system diseases (320–389) | 11 | 17.56 | 0.63 (0.31 to 1.12) | 0.13 |
| All CVD (390–459) | 514 | 475.03 | 1.08 (0.99 to 1.18) | 0.08 |
| Hypertensive disease (401–405) | 13 | 4.87 | 2.67 (1.42 to 4.57) | <0.01 |
| Ischaemic heart disease (410–414) | 346 | 322.36 | 1.07 (0.96 to 1.19) | 0.20 |
| Cerebrovascular disease (430–438) | 71 | 68.88 | 1.03 (0.81 to 1.30) | 0.83 |
| Other CVD | 84 | 78.93 | 1.06 (0.85 to 1.32) | 0.60 |
| Pneumonia (480–486) | 29 | 26.62 | 1.09 (0.73 to 1.56) | 0.70 |
| COPD and asthma (490–496) | 25 | 43.22 | 0.58 (0.37 to 0.85) | <0.01 |
| All digestive diseases (520–579) | 42 | 43.66 | 0.96 (0.69 to 1.30) | 0.88 |
| Nephritis and nephrosis (580–587) | 7 | 6.36 | 1.10 (0.44 to 2.27) | 0.90 |
| Other genitourinary diseases (590–629) | 11 | 12.78 | 0.86 (0.43 to 1.54) | 0.75 |
| All causes | 1097 | 1071.89 | 1.02 (0.96 to 1.09) | 0.45 |
*Adjusted for age and calendar-year at risk by stratification.CNS, central nervous system; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular diseases; NHL, non-Hodgkin's lymphoma; SMR, standardised mortality ratio.
SIR for various cancers and 95% CIs, male Port Hope workers (1969–1999)
| Cause | Observed* | Expected† | SIR (95% CI) | p Value |
|---|---|---|---|---|
| Lip cancer | 5 | 6.12 | 0.82 (0.27 to 1.91) | 0.85 |
| Oesophageal cancer | 5 | 6.23 | 0.80 (0.26 to 1.87) | 0.82 |
| Stomach cancer | 13 | 17.38 | 0.75 (0.40 to 1.28) | 0.35 |
| Colon cancer | 33 | 39.78 | 0.83 (0.57 to 1.16) | 0.32 |
| Rectal cancer | 22 | 23.95 | 0.92 (0.58 to 1.39) | 0.79 |
| Pancreatic cancer | 10 | 12.37 | 0.81 (0.39 to 1.49) | 0.62 |
| Laryngeal cancer | 11 | 9.55 | 1.15 (0.58 to 2.06) | 0.72 |
| Lung cancer | 108 | 99.92 | 1.08 (0.89 to 1.30) | 0.44 |
| Malignant melanoma | 11 | 8.24 | 1.33 (0.67 to 2.39) | 0.42 |
| Prostate cancer | 89 | 94.32 | 0.94 (0.76 to 1.16) | 0.63 |
| Kidney cancer | 5 | 13.11 | 0.38 (0.12 to 0.89) | 0.02 |
| Bladder and other urinary cancer | 30 | 29.59 | 1.01 (0.68 to 1.45) | 0.99 |
| Bladder cancer | 26 | 28.54 | 0.91 (0.60 to 1.33) | 0.72 |
| Brain and other CNS cancer | 9 | 7.43 | 1.21 (0.55 to 2.30) | 0.66 |
| Brain cancer | 9 | 6.91 | 1.30 (0.60 to 2.47) | 0.52 |
| NHL | 15 | 15.35 | 0.98 (0.55 to 1.61) | >0.99 |
| All leukaemia | 10 | 12.23 | 0.82 (0.39 to 1.50) | 0.65 |
| All cancers | 418 | 453.52 | 0.92 (0.84 to 1.01) | 0.10 |
*The number of observed cases reflects the incidence of newly diagnosed cancer cases where a single individual can contribute more than one case of cancer.
†Adjusted for age and calendar year at risk by stratification.
CNS, central nervous system; NHL, non-Hodgkin's lymphoma; SIR, standardised incidence ratio.
Risks of lung cancer mortality (1950–1999) and cancer incidence (1969–1999) and 95% CIs by category of cumulative RDP exposure and type of primary exposure, male Port Hope workers
| Cumulative exposure (WLM) | Mean exposure (WLM) | Number of deaths | Number of person-years | RR* and 95% CI | p Value |
|---|---|---|---|---|---|
| 0.00– | 0 | 16 | 30688 | 1.00 (reference) | 0.56† |
| 0.01– | 1.2 | 33 | 28666 | 0.80 (0.41 to 1.58) | |
| 3.5– | 7.9 | 30 | 12460 | 1.67 (0.34 to 3.33) | |
| 15– | 26.9 | 11 | 6518 | 1.37 (0.58 to 3.25) | |
| 50.0–626.0 | 177.9 | 9 | 4668 | 1.42 (0.53 to 3.84) | |
| All workers with no mining experience | 15.9 | 99 | 82999 | 0.21 (<−0.45 to 1.59) | 0.54‡ |
| Uranium workers | 9.6 | 78 | 64880 | 0.39 (<−1.22 to 4.52) | 0.83§ |
| Radium workers | 26.8 | 21 | 18119 | 0.21 (<−0.34 to 1.63) | |
*Adjusted for age at risk, calendar year at risk and duration of employment by stratification.
†p Values of the test of linear trend based on mean values for exposure categories.
‡p Values from the likelihood ratio test comparing models with and without exposure variable.
§p Values from the likelihood ratio test for interaction by subcohort.
¶Number of cases based on the earliest cancer diagnosis where each subject could contribute at most one cancer.
ERR/100 WLM, excess relative risk per 100 WLM; RDP, radon decay products; RR, relative risk; WLM, working level months.
Excess relative risk estimates and 95% CIs for RDP exposures and γ-ray dose for various causes of death (1950–1999)
| RDP exposures | γ-Ray dose | ||||
|---|---|---|---|---|---|
| Cause of death | Number of deaths | ERR/100 WLM* | p Value† | ERR/Sv‡ | p Value† |
| Solid cancers | 225 | 0.10 (<−0.18, 0.66) | 0.54 | 0.12 (<−0.35, 0.98) | 0.66 |
| Stomach cancer | 14 | 0.43 (<−0.16, 7.48) | 0.66 | 0.81 (<−1.41, 13.07) | 0.60 |
| Colon cancer | 22 | −0.16 (<−0.16, 3.40) | 0.74 | 1.65 (<−2.16, 23.45) | 0.40 |
| Rectal cancer | 15 | 0.21 (<−0.34, 2.31) | 0.50 | 0.19 (<−0.61, 3.90) | 0.73 |
| Pancreatic cancer | 10 | n.c. | −0.29 (<−0.29, 8.11) | 0.55 | |
| Laryngeal cancer | 5 | n.c. | n.c. | ||
| Prostate cancer | 21 | 0.58 (<−0.96, 8.07) | 0.48 | 0.72 (<−1.47, 8.99) | 0.53 |
| Kidney cancer | 6 | −0.16 (<−0.39, 49.51) | 0.92 | n.c. | |
| Bladder cancer | 10 | −0.15 (<−0.39, 33.14) | 0.90 | −0.29 (<−0.29, 19.55) | 0.76 |
| Brain cancer | 5 | −0.15 (<−0.34, 1.74) | 0.90 | ||
| All haematological cancers | 17 | −0.16 (<−0.34, 14.27) | 0.79 | −0.29 (<−0.29, 15.31) | 0.76 |
| NHL | 7 | −0.16 (<−0.34, 10.19) | 0.80 | −0.29 (<−0.29, 20.92) | 0.80 |
| Leukaemia | 6 | n.c. | n.c. | ||
| All CVD | 514 | 0.10 (−0.05, 0.32) | 0.22 | 0.19 (−0.07, 0.55) | 0.17 |
| Ischaemic heart disease | 346 | 0.16 (−0.05, 0.50) | 0.16 | 0.31 (−0.05, 0.88) | 0.10 |
| Stroke | 71 | −0.10 (<−0.34, 0.38) | 0.57 | −0.29 (<−0.29, 0.33) | 0.26 |
| Other CVD | 97 | 0.12 (<−0.18, 0.68) | 0.49 | 0.29 (−0.18, 1.27) | 0.31 |
| All digestive diseases | 42 | −0.16 (<−0.34, 0.79) | 0.49 | −0.23 (<−0.29, 1.66) | 0.67 |
*Model adjusted for age at risk, calendar year at risk and duration of employment by stratification. γ-Ray doses were not included in the model.
†p Values from the likelihood ratio test comparing nested model with and without the exposure term.
‡Model adjusted for age at risk, calendar year at risk and duration of employment by stratification. RDP exposures were not included in the model.
CVD, cardiovascular diseases; ERR/Sv, excess relative risk per 1 sievert; ERR/100 WLM, excess relative risk per 100 WLM; n.c., model did not converge; NHL, non-Hodgkin's lymphoma; RDP, radon decay products; WLM, working level months.